期刊文献+

白介素-27在多发性骨髓瘤中的表达及其临床意义 预览

EXPRESSION AND CLINICAL SIGNIFICANCE OF INTERLEUKIN-27 IN PATIENTS WITH MULTIPLE MYELOMA
在线阅读 免费下载
分享 导出
摘要 目的:探讨初治多发性骨髓瘤(MM)患者治疗前后白介素-27(IL-27)的水平及其临床意义.方法:选择对照组(健康体检者)40例,初治MM患者41例,采用ELISA法检测对照组及初治MM组治疗前后血清IL-27水平,并分析治疗前患者不同年龄、分型、血红蛋白、血肌酐、乳酸脱氢酶(LDH)、β2-微球蛋白(β2-MG)及D-S分期的血清IL-27水平.结果:血清IL-27水平在对照组为(18.32±6.70) ng/L,MM治疗前为(11.23±2.55) ng/L,治疗后有效组为(17.68±4.81) ng/L,治疗后无效组为(11.80±5.60) ng/L,治疗有效组较治疗前血清IL-27水平升高,差异有统计学意义(P<0.05),而治疗无效组较治疗前差异不明显(P>0.05).治疗前血清IL-27水平在血红蛋白≥100 g/L与<100 g/L、LDH≥245 U/L与<245 U/L、β2-MG≥5.5 mg/L与<5.5 mg/L组间比较,差异均有统计学意义(均P<0.05).而在年龄≥60岁与<60岁,血肌酐≥177 μmol/L与<177 μmol/L,D-S分期Ⅰ、Ⅱ、Ⅲ期及分型组间比较差异均无统计学意义(均P>0.05).结论:MM患者血清IL-27水平下调,并与血红蛋白、LDH、β2-MG有关,提示其可能具有抗肿瘤作用. Objective: To explore the expression of interleukin-27(IL-27) and its clinical significance in multiple myeloma(MM)before and after treatment. Methods: 40 healthy people were chosen as control group and 41 cases MM with primary treatment were also enrolled in this study. Serumal level of IL-27 in the control group and MM group before and after treatment were detected by ELISA method. Meanwhile, analysing the correlation between IL-Z7 expression and the clinical characteristic of patients (including age, types,hemoglobin,creatinine,LDH,β2-microglobulin(β2-MG) and D-S stage). Results: The level of IL-27 in MM group before treatment (11.23+2.55) ng/L was lower than that of control group(18.32+6.70) ng/L. After treatment, the level of IL-27 in the effective group were (17.68+4.81) ng/L and it was significantly higher than the ineffective group(11. 80+5.60) ng/L ( P 〈0.05), and there not different between the invalid group and primary treatment group( P 〉0.05). Furthermore, the level of IL-27 in newly diagnosed patients with MM were significantly different between hemoglobin ≥100 g/L and〈100 g/L, LDH≥245 U/L and〈245 U/L, β2-MG≥5.5 mg/L and 〈5.5 mg/L,respectively( P〈0. 05). But there were not different between age ≥60 and〈60 years, creatinine≥177 μmol/L and〈177 μmol/L,neither during D-S stage Ⅰ , Ⅱ ,Ⅲand type IgG, IgA,no secretion,light chain( P 〉0.05). Conclusion:IL-27 dedines in MM,which has an anti-tumor effect and correlates with hemoglobin, LDH,β-MG.
作者 黄艳平 黄锦雄 韦夙 韦敏 杨飞燕 刘琴 王健琨 Huang Yanping, Huang Jinxiong, Wei Su, Wei Min, Yang Feiyan, Liu Qin, Wang Jiankun. (Department of Hematology, People' s Hospital of Liuzhou, Liuzhou 545006, China)
出处 《广西医科大学学报》 CAS 2015年第3期388-390,共3页 Journal of Guangxi Medical University
基金 广西壮族自治区卫生厅科研资助项目(N0.Z-2012578)
关键词 白介素-27 多发性骨髓瘤 预后 LDH Β2-MG interleukin-27 multiplemyeloma prognosis LDH β2-MG
作者简介 通信作者
  • 相关文献

参考文献7

二级参考文献18

  • 1Greipp PR,San Miguel J,Durie BG,et al.International staging system for multiple myeloma[J].J Clin Oncol,2005,23(15):3412. 被引量:1
  • 2韩敬淑等.中华血液学杂志,1982,8(4):206-206. 被引量:1
  • 3Shaw MT,et al.Cancer,1974,33(3):619. 被引量:1
  • 4Shaughnessy J,Tian E,Sawyer J,et al.Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma:early results of total therapy II[J].Br J Haematol,2003,120(1):4. 被引量:1
  • 5Astrom M,Bed in L,Nilsson I,et a1.Treatment long-term outcomeand prognostic variable in 214 unselected AML patients in Sweden[J].B J Cancer,2000,82:1387. 被引量:1
  • 6周嘉芷.多发性骨髓瘤的诊断与治疗[J].1996,35(3):206-206. 被引量:1
  • 7Swerdlow S H,et al.WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.IARC:Lyon 2008. 被引量:1
  • 8Stumhofer JS, Hunter CA. Advances in understanding theanti - inflamatory properties of IL - 27. Immunol Lett, 2008,117: 123-130. 被引量:1
  • 9Cocco C, Giuliani N, Di Carlo E, et al. Interleukin-27 actsas multifunctional antitumor agent in multiple myeloma.Clin Cancer Res, 2010, 16: 4188-4197. 被引量:1
  • 10Wojno ED, Hunter CA. New directions in the basic andtranslational biology of interleukin - 27. Trends Immunol,2012, 33: 91-97. 被引量:1

共引文献92

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈